October 11, 2026
Bonus Content: Election Bets Have an Insider Trading Problem. That Changes the Price.
Dear Reader,
Every single day a new drug sits waiting for FDA approval can cost the company behind it approximately $500,000.
Miss by a month and the meter can run to $15 million. Miss by a quarter and it can reach $45 million.
Now you understand why this hidden AI company may have big pharma trapped in the best possible way for investors.
See why this $500,000-a-day problem has my full attention.
I am Alexander Green, Chief Investment Strategist of The Oxford Club for more than two decades. I bought Apple in 1996, and Amazon and Netflix below $3 split-adjusted.
Those wins taught me to look beyond the loudest hardware story and ask a more important question: Which company becomes so embedded in an industry that removing it feels reckless?
I believe I have found one.
Nineteen of the top 20 biopharma companies run regulatory operations through its platform. Their clinical data, submissions, and compliance records live inside the system.
Now comes the pressure point: customers are being moved from a legacy product to the company’s newer AI-powered platform. More than 125 customers are already live, and Clinical Data AI applications are scheduled to go live in December 2026.
When one lost day can carry a six-figure cost, switching to an unproven rival could be an executive-level gamble.
Discover why big pharma may be unable to walk away from this platform.
This is Phase 2 of the AI boom: not building chips, but using AI to take control of an essential, expensive workflow. The deeper the platform goes, the harder it may become to replace.
That December rollout gives investors a concrete reason to pay attention now, while the company is still hiding in plain sight.
The December rollout is on the calendar. The stock is still hiding in plain sight.
See the complete biopharma AI case before the December rollout.
Good investing,
Alexander Green
Chief Investment Strategist, The Oxford Club
P.S. One day of FDA delay can cost roughly $500,000. This platform already sits inside 19 of the top 20 biopharma giants, and its Clinical Data AI rollout is scheduled for December. See the stock behind the rollout here.
Election Bets Have an Insider Trading Problem. That Changes the Price.
Markets do not need certainty. They only need an edge. And right now, the largest structural edge in American financial markets may belong to a campaign staffer who knows whether Tuesday’s endorsement announcement is happening before anyone on Kalshi or Polymarket does.
A report by the nonpartisan Anti-Corruption Data Collective found that a small share of accounts is driving a large share of trading volume in 2026 congressional prediction markets across Kalshi and Polymarket. Bets include candidate withdrawals, endorsements, rally speeches, and whether debates will occur. These are not probabilistic forecasts about who wins a Senate seat. Unlike election outcomes, some of these questions can have answers known in advance to people working on campaigns and events. That is a structurally different risk than a binary outcome contract on House control. It is, in options terms, a trade where one counterparty may hold a deeply in-the-money position before the order is ever placed.
What the Contracts Actually Cost
Each contract is priced between $0.01 and $0.99 and pays out $1.00 if the outcome you picked happens, or nothing if it does not, so the price works as the market’s estimate of how likely that outcome is. A conventional binary options contract on a CME-listed instrument prices the same probability distribution, but with regulated access to surveillance, position limits, and a counterparty framework the CFTC has refined over decades. Kalshi holds the status as a CFTC Designated Contract Market, the same regulatory category used by the Chicago Mercantile Exchange. The category is the same. The information environment is not.
Claims about typical bid-ask spreads and fee-driven differences between Polymarket and Kalshi vary by contract, liquidity, and moment-in-time conditions. The more durable point is structural: in thin books, even a few cents of spread is a meaningful tax on expected value, and in markets tied to pre-scheduled, potentially knowable events, that tax can be an indirect premium for trading against better-informed flow. Rational pricing of insider risk would tend to widen spreads, not compress them.
The Regulatory Clock
These incentives came to national attention this summer when federal authorities accused a former White House teleprompter operator of using advance access to President Trump’s prepared remarks to trade on Kalshi “mention markets.” In a settlement announced in late August 2026, the CFTC ordered him to turn over more than $100,000 in profits and pay a $65,000 civil penalty. The platforms have enforcement mechanisms. The question is whether those mechanisms can outrun growing participation and increasingly granular contracts into November.
On June 10, 2026, the CFTC issued a proposed rule regarding the types of event contracts that can be listed on CFTC-registered prediction markets. The public comment period closed July 27, 2026. A final rule is not yet in place, which means the administration is finalizing a framework for venues that are, right now, running live contracts on outcomes where information asymmetry can be measured.
The DKNG Angle
DraftKings launched its CFTC-regulated DKeX prediction market exchange, which Bank of America estimates could generate $600 million to $800 million in revenue by 2027. Bank of America upgraded DraftKings to buy from neutral and kept its $27 price target, citing improving prospects for prediction markets and a more attractive risk-reward after a sharp decline in the stock over the past year. The BofA bull case is elegant: even a regulatory crackdown could remove what the analyst described as a lingering terminal-value overhang, potentially supporting a higher valuation multiple.
Options Market Analysis: DKNG
DKNG was trading around $19.58 as of the latest available quote (Oct. 10, 2026). Specific implied-volatility readings depend on the exact options series and the moment you sample them, but the larger takeaway holds: with Washington risk and an earnings catalyst clustered in early November, the market is being asked to price two catalysts inside a tight window. DraftKings’ next earnings report is widely expected around Thursday, November 5, 2026, though the company has not confirmed the date.
Structured Trade Framework
Bull case: If you believe the CFTC’s proposed rule entrenches Kalshi and DraftKings as the regulated incumbents while freezing out competitors, a defined-risk long structure on DKNG into the early-November earnings window captures both the regulatory clarity and any prediction market volume surge around election results. A bull call spread anchored near $20 with a $25 strike targets the BofA price objective while capping downside to the debit paid.
Bear case: For traders expecting congressional action to restrict “knowable event” contracts specifically, elevated IV into earnings creates conditions where buying puts or a bear put spread is the lower-cost directional vehicle. The thesis rests on regulatory restriction hitting DKeX volume before it scales.
Neutral case: Elevated IV on a stock with binary regulatory outcomes suggests an iron condor expiring post-earnings is the structure that benefits if Washington produces ambiguity rather than resolution. Defined risk on both sides, premium collected from both the bull and bear camps pricing in moves that may not materialize.
Risk and Forward Outlook
The insider-trading concern is not speculative. Reporting this year highlighted well-timed trading around geopolitical events, and House Oversight has opened an investigation into insider-trading controls at Kalshi and Polymarket. Separately, CNN and other outlets have reported on a CFTC inquiry tied to pardon-related prediction-market trading involving a former lawmaker. The direction of political pressure is toward restriction, not expansion. What is uncertain is whether federal rulemaking moves faster than the political cycle that has exposed its gaps.
Action Checklist
- Monitor CFTC final rule publication: the comment period on the June 10, 2026 proposal closed July 27, 2026, and final rules typically specify an effective date after Federal Register publication.
- Track DKNG implied volatility into early November; a sharp expansion ahead of the expected November 5 earnings window would signal the market pricing more decisive regulatory news.
- Assess bid-ask spreads on “knowable event” contracts as a real-time signal of whether insider-trading concerns are being priced in or ignored.
- Any defined-risk DKNG structure should account for early-November election results and the early-November earnings window as a compressed dual-catalyst period.
- Watch for congressional legislation targeting specific contract categories: a bill restricting endorsement or rally contracts would undercut the DKeX revenue build embedded in bullish 2027 estimates.
